Fluorine Patents (Class 424/1.89)
-
Publication number: 20130177501Abstract: The present invention provides a method useful in the diagnosis and/or monitoring of mood disorders wherein there is an abnormal expression of PBR. The method of the invention is useful in the differential diagnosis of said mood disorders and other conditions where there is no abnormal expression of PBR but where the symptoms may be similar to those of said mood disorder.Type: ApplicationFiled: September 23, 2011Publication date: July 11, 2013Applicant: GE HEALTHCARE LIMITEDInventor: Paul Alexander Jones
-
Publication number: 20130164217Abstract: Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.Type: ApplicationFiled: December 20, 2012Publication date: June 27, 2013Applicant: Meso Scale Technologies, LLCInventors: Robert M. Umek, Pankaj Oberoi
-
Publication number: 20130164218Abstract: This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein.Type: ApplicationFiled: December 27, 2012Publication date: June 27, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Patent number: 8470297Abstract: This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.Type: GrantFiled: September 10, 2010Date of Patent: June 25, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Brian DerHua Lu, Siu-Long Yao, Cynthia Seidel-Dugan, Yan Wang
-
Publication number: 20130156700Abstract: A method for positron emission tomography (PET) imaging of LRRK2 in tissue of a subject, the method comprising: administering a compound of formula I, formula II or formula III, or a pharmaceutically acceptable salt thereof to the subject, wherein the compound includes at least one C11 or F18 label thereon; allowing the compound to penetrate into the tissue of the subject; and collecting a PET image of the CNS or brain tissue of the subjectType: ApplicationFiled: November 28, 2012Publication date: June 20, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Publication number: 20130156701Abstract: The present invention provides a method for preparing [18F]—N-(4-fluorobutyl)ethacrynic amide which is prepared from radiofluorination and deprotection of the precursor tosylate N-Boc-N-[4-(toluenesulfonyloxy)-butyl)ethacrynic amide], obtained from ethacrynic acid via 6-step synthesis in 39% yield, in a radiochemical yield of 44%, aspecific activity of 48 GBq/?mol and radiochemical purity of 98%. The present invention further provides a composition for positron emission tomography (PET) of an animal models of a tumor liver or a liver disease, comprising [18F]—N-(4-fluorobutyl)ethacrynic amide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: NATIONAL TSING HUA UNIVERSITYInventor: National Tsing Hua University
-
Publication number: 20130156699Abstract: The present invention relates to Radiolabeled Compounds labeled with fluorine, bromine, iodine, carbon, or tritium isotopes and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.Type: ApplicationFiled: November 5, 2012Publication date: June 20, 2013Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Joseph John MANN, J.S. Dileep KUMAR
-
Patent number: 8465726Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: April 22, 2010Date of Patent: June 18, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
-
Publication number: 20130149244Abstract: The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.Type: ApplicationFiled: May 11, 2011Publication date: June 13, 2013Applicant: Lantheus Medical Imaging, Inc.Inventors: Ajay Purohit, Pedro Benites, Edward H. Cheesman, Joel Lazewatsky, L. Veronica Lee, Richard R. Cesati, Richard J. Looby, Heike S. Radeke
-
Publication number: 20130149239Abstract: The present invention relates to novel 5-pyrrolidinylsulfonyl isatin derivatives, non-peptidyl Caspase binding Radioligands (CbRs) and CbR-transporter conjugates derived from said isatin derivatives, diagnostic compositions comprising said compounds of the invention and their use for non-invasive diagnostic imaging.Type: ApplicationFiled: November 26, 2012Publication date: June 13, 2013Applicant: Universitatsklinikum MunsterInventor: Universitatsklinikum Munster
-
Publication number: 20130149243Abstract: This invention relates to methods, which provide access to F-18 labeled glutamic acid derivatives.Type: ApplicationFiled: November 6, 2010Publication date: June 13, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Mathias Berndt, Heribert Schmitt-Willich, Matthias Friebe, Keith Graham, Thomas Brumby, Christina Hultsch, Hans-Jürgen Wester, Franziska Wagner
-
Patent number: 8460635Abstract: Synthetic peptidomimetic derivatives and phenyl group derivatives of Fenretinide (4-HPR) are disclosed, as are their uses as therapeutic, diagnostic and imaging agents for cancer and other diseases.Type: GrantFiled: March 11, 2009Date of Patent: June 11, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Ganjam V. Kalpana, Bhaskar C. Das
-
Publication number: 20130129625Abstract: The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states.Type: ApplicationFiled: December 18, 2012Publication date: May 23, 2013Applicants: HAMMERSMITH IMANET LIMITED, GE HEALTHCARE LIMITEDInventors: GE Healthcare Limited, Hammersmith Imanet Limited
-
Publication number: 20130129626Abstract: The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states.Type: ApplicationFiled: December 18, 2012Publication date: May 23, 2013Applicants: HAMMERSMITH IMANET LIMITED, GE HEALTHCARE LIMITEDInventors: GE Healthcare Limited, Hammersmith Imanet Limited
-
Patent number: 8444956Abstract: The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.Type: GrantFiled: May 17, 2012Date of Patent: May 21, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Patent number: 8444955Abstract: The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.Type: GrantFiled: September 9, 2008Date of Patent: May 21, 2013Assignee: GE Healthcare LimitedInventors: Alan Cuthbertson, Magne Solbakken, Dag Erlend Olberg
-
Publication number: 20130123618Abstract: This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[18F]FACPC and (1R,2R) anti-2-[18F]FACPC.Type: ApplicationFiled: January 2, 2013Publication date: May 16, 2013Applicant: EMORY UNIVERSITYInventor: EMORY UNIVERSITY
-
Publication number: 20130115168Abstract: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to arylammonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the ammonium compound is a tetraaryl ammonium salt. Another aspect of the invention relates to arylsulfonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the sulfonium compound is a triaryl sulfonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.Type: ApplicationFiled: September 4, 2012Publication date: May 9, 2013Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Patent number: 8435490Abstract: Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.Type: GrantFiled: June 4, 2008Date of Patent: May 7, 2013Assignee: The Johns Hopkins UniversityInventors: John Martin Abraham, Stephen J. Meltzer
-
Patent number: 8435493Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: GrantFiled: November 15, 2010Date of Patent: May 7, 2013Assignee: Emory UniversityInventor: Mark M. Goodman
-
Publication number: 20130101510Abstract: Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.Type: ApplicationFiled: October 8, 2012Publication date: April 25, 2013Applicants: The Regents of the University of California, Genzyme CorporationInventors: Krys BANKIEWICZ, Janet Cunningham
-
Publication number: 20130101509Abstract: The present invention relates to in vivo imaging and radiotherapeutic methods and agents which target the enzyme aldehyde dehydrogenase (ALDH) and that are suitable for the in vivo imaging of tumours and treatment of cancer.Type: ApplicationFiled: September 19, 2012Publication date: April 25, 2013Applicants: GENERAL ELECTRIC COMPANY, GE HEALTHCARE LIMITEDInventors: GE HEALTHCARE LIMITED, GENERAL ELECTRIC COMPANY
-
Publication number: 20130101508Abstract: Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.Type: ApplicationFiled: April 15, 2010Publication date: April 25, 2013Applicant: Lantheus Medical Imaging, Inc.Inventors: James F. Castner, Dianne D. Zdankiewicz, James E. Anderson
-
Patent number: 8420052Abstract: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.Type: GrantFiled: July 24, 2009Date of Patent: April 16, 2013Assignee: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Wei Zhang, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Kai Chen, Anjana Sinha, Eric Wang, Gang Chen, Peter J. H. Scott, Henry Clifton Padgett, Qianwa Liang, Zhiyong Gao, Tieming Zhao, Chunfang Xia, Vani P. Mocharla
-
Publication number: 20130089501Abstract: The invention provides a process for the production of an 18F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I) SOLID SUPPORT-LINKER-X-TRACER??(I) wherein X is a group which promotes nucleophilic substitution at a specific site on the attached TRACER and the TRACER is of formula (A)Type: ApplicationFiled: November 28, 2012Publication date: April 11, 2013Applicants: HAMMERSMITH IMANET LIMITED, GE HEALTHCARE LIMITEDInventors: GE HEALTHCARE LIMITED, HAMMERSMITH IMANET LIMITED
-
Publication number: 20130089502Abstract: A functional PET imaging method is disclosed for differentiation between bilateral hyperplasia and unilateral adenoma comprising (1) introducing a radioactively labelled CYP11 B2 (aldosterone synthase) inhibitor which binds selectively to CYP11 B2 (aldosterone synthase) relative to CYP11 B1 (11?-hydroxylase) into a mammal with adrenal glands and (2) conducting positron emission tomography (PET) in the region of the adrenal glands to obtain a functional PET image of the adrenal glands. Also disclosed are radioactive tracer compounds suitable for use in this method, precursors for making the same, and a process for making the radioactive tracer compounds capable of being conducted as a rapid one-pot reaction.Type: ApplicationFiled: June 1, 2011Publication date: April 11, 2013Applicants: UNIVERSITAT DES SAARLANDES, JULIUS-MAXIMILIANS-UNIVERSITATInventors: Bruno Allolio, Stefanie Hahner, Andreas Schirbel, Rolf Hartmann, Christina Zimmer
-
Publication number: 20130084245Abstract: The present invention provides methods of monitoring A?-directed immunotherapy. The methods involve administering a PET ligand that binds to amyloid deposits and detecting the PET ligand in the brain to provide an indication of the level and/or distribution of amyloid deposits. Surprisingly, the data in the present application show that a statistically significant reduction in amyloid deposits occurs early and consistently among patients following initiation of treatment before statistically significant effects of most if not all other markers are detectable. In consequence, the present methods allow early detection of whether a patient is responding to the A?-directed immunotherapy and if necessary adjustment of the immunotherapy regime.Type: ApplicationFiled: February 25, 2011Publication date: April 4, 2013Applicants: Wyeth LLC, Janssen Alzheimer ImmunotherapyInventors: Ronald Black, Michael Grundman
-
Patent number: 8409547Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): R*-L2-C?N+—O???(II) or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: GrantFiled: June 25, 2012Date of Patent: April 2, 2013Assignee: Hammersmith Imanet LimitedInventors: Matthias Eberhard Glaser, Erik Arstad
-
Publication number: 20130071327Abstract: This invention relates to homoglutamic acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.Type: ApplicationFiled: November 8, 2010Publication date: March 21, 2013Applicant: PIRAMAL IMAGING SAInventors: Heribert Schmitt-Willich, Niels Böhnke, Norman Koglin, Andre Müller, Mathias Berndt, Matthias Friebe, Lutz Lehmann
-
Patent number: 8398956Abstract: The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for 18F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to 18F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents.Type: GrantFiled: December 2, 2011Date of Patent: March 19, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20130064770Abstract: The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.Type: ApplicationFiled: May 26, 2011Publication date: March 14, 2013Applicant: GE HEALTHCARE LIMITEDInventors: Ian Martin Newington, Duncan George Wynn, Robert James Domett Nairne, Benedicte Guilbert, Subrata Mandal, Jinto Jose, Sunderaraman Varadarajan, Chitralekha Rangaswamy, Helen Betts, Rebecca Davis
-
Publication number: 20130064769Abstract: The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.Type: ApplicationFiled: February 8, 2011Publication date: March 14, 2013Applicant: Lantheus Medical Imaging, IncInventors: Richard R. Cesati, Edward H. Cheesman, Joel Lazewatsky, Heike S. Radeke, James F. Castner, Enrico Mongeau, Dianne D. Zdankiewicz, Robert Wilburn Siegler, Marybeth Devine
-
Patent number: 8383083Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: June 30, 2011Date of Patent: February 26, 2013Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Publication number: 20130045164Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or Formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or Formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.Type: ApplicationFiled: October 23, 2012Publication date: February 21, 2013Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventor: UNIVERSITY OF PITTSBURGH - OF THE COMM
-
Publication number: 20130045165Abstract: 4-Fluoro-4-phenylpiperidin-1-yl ? antagonists of general structure as well as pharmaceutical compositions comprising compounds of formula I, are disclosed. These compounds and compositions are useful as treatments of conditions or diseases associated with binding opioid receptors including pain, obesity, hyperalgesia, inflammation, osteoarthritis, drug addiction, and cancer. These compounds and compositions are also useful as treatments for tardive dyskinesia.Type: ApplicationFiled: April 29, 2011Publication date: February 21, 2013Applicant: KINENTIA BIOSCIENCES, LLCInventor: David J. Fairfax
-
Patent number: 8372380Abstract: Radiolabeled tracers for sulfotransferases (SULTs), their synthesis, and their use are provided. Included are substituted phenols, naphthols, coumarins, and flavones radiolabeled with 18F, 123I, 124I, 125I, or 11C. Also provided are in vivo techniques for using these and other tracers as analytical and diagnostic tools to study sulfotransferase distribution and activity, in health and disease, and to evaluate therapeutic interventions.Type: GrantFiled: March 31, 2008Date of Patent: February 12, 2013Assignee: The Regents of the University of CaliforniaInventors: Jorge R. Barrio, Vladimir Kepe, Gary W. Small, Nagichettiar Satyamurthy
-
Patent number: 8366934Abstract: A method extracts out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step. The eluting solution is a low water content, preferably <3% water, organic solution containing at least: a first compound (A) which is a tertiary alcohol-function bearing molecule, a second compound (B) which is a phase transfer agent suitable for radiolabeling and which is necessary to the anion exchange process.Type: GrantFiled: February 19, 2008Date of Patent: February 5, 2013Assignees: Trasis S.A., Universite de liegeInventors: Joel Aerts, Christian LeMaire, Steve Lignon, André Luxen, Jean-Luc Morelle, Gauthier Philippart, Samuel Voccia
-
Publication number: 20130028837Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: ApplicationFiled: August 10, 2012Publication date: January 31, 2013Applicant: Lantheus Medical Imaging, Inc.Inventors: Heike S. Radeke, David S. Casebier, Michael T. Azure, Douglas D. Dischino
-
Publication number: 20130028838Abstract: This invention relates to radioactive tyrosine derivatives for imaging bone metastases, a method for imaging or diagnosing bone metastases, compositions and kits for imaging bone metastases.Type: ApplicationFiled: February 4, 2011Publication date: January 31, 2013Applicant: PIRAMAL IMAGING SAInventors: Sabine Zitzmann-Kolbe, Keith Graham
-
Patent number: 8361443Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: June 15, 2005Date of Patent: January 29, 2013Assignee: GE Healthcare ASInventor: Alan Cuthbertson
-
Patent number: 8357350Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.Type: GrantFiled: February 12, 2009Date of Patent: January 22, 2013Assignee: General Electric CompanyInventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Kenneth Michael Fish, Nicole Evelyn Barnhardt, John V. Frangioni, Carrie S. Vooght
-
Publication number: 20130011336Abstract: Agents and methods for imaging a cell and/or a portion of tissue characterized by fibrosis, as well as to agents and methods for determining and/or diagnosing fibrotic diseases are disclosed herein. Also disclosed herein are polymer conjugates that can include a detectable label, a retinoid and a polymer. The polymer conjugates can be used to image a portion of tissue, deliver a detectable label to a portion of tissue or a cell and/or diagnosis a condition or disease.Type: ApplicationFiled: September 11, 2009Publication date: January 10, 2013Applicant: NITTO DENKO CORPORATIONInventors: Yoshiro Niitsu, Lei Yu, Gang Zhao, Sang Van, Xinghe Wang, Jian Liu, Sanjib Kumar Das, Yasunobu Tanaka, Keiko Kajiwara, Hirokazu Takahashi, Miyono Miyazaki
-
Publication number: 20130004422Abstract: This invention provides benzothiazole derivative compounds, compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for detecting amyloid deposit(s) and for diagnosing a disease, disorder or condition characterized by amyloid deposit(s).Type: ApplicationFiled: July 12, 2012Publication date: January 3, 2013Inventors: William E. KLUNK, Chester A. MATHIS, JR., Yanming WANG
-
Patent number: 8343515Abstract: A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.Type: GrantFiled: November 17, 2009Date of Patent: January 1, 2013Assignee: Oxygen Biotherapeutics, Inc.Inventors: Gary Huvard, Richard Kiral, Maxine Quitaro, Deborah P. Thompson, Aharon Grossman, Gary Clauson, Gurbhagat Sandhu
-
Patent number: 8343459Abstract: A method for producing a radioactive diagnostic imaging agent which contains a radioactive halogen-labeled amino acid compound as an effective ingredient and has a composition that can inhibit radiolysis of the effective ingredient, thereby further improving stability, is provided. Disclosed is a method for producing a radioactive diagnostic imaging agent, comprising a solution preparation step of preparing a solution containing a radioactive halogen-labeled amino acid compound, and a dilution step of diluting the solution containing the radioactive fluorine-labeled organic compound in order to adjust radioactive concentration thereof, which further comprises an acid addition step of adding an acid to the solution containing the radioactive fluorine-labeled organic compound, after the solution preparation step and before the dilution step, wherein the acid is added in the acid addition step in an amount sufficient to adjust the pH of the solution resulting from the dilution step to 2.0-5.Type: GrantFiled: February 12, 2008Date of Patent: January 1, 2013Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Daisaku Nakamura, Soichi Nakamura, Masahito Toyama, Akio Hayashi
-
Patent number: 8343457Abstract: The present method for determining the efficacy of therapy in the treatment of amyloidosis involves administering to a patient in need thereof a compound of formula (I) or formula (II) or structures 1-45 and imaging the patient. After said imaging, at least one anti-amyloid agent is administered to said patient. Then, an effective amount of a compound of formula (I) or formula (II) or structures 1-45 is administered to the patient and the patient is imaged again. Finally, baseline levels of amyloid deposition in the patient before treatment with the anti-amyloid agent are compared with levels of amyloid deposition in the patient following treatment with the anti-amyloid agent.Type: GrantFiled: March 6, 2012Date of Patent: January 1, 2013Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: William E. Klunk, Chester A. Mathis, Jr.
-
Patent number: 8343460Abstract: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use in PET imaging. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules may be labeled and utilized. Preferably, the F-18 is attached to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety. In other embodiments, the metal may first be attached to the chelating group and subsequently the F-18 bound to the metal. More preferably, the F-18 label moiety may be attached to a targetable conjugate that is used for pretargeting in combination with a bispecific or multispecific antibody. The F-18-metal labeled molecules are stable in human serum at 37° C.Type: GrantFiled: February 29, 2012Date of Patent: January 1, 2013Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg
-
Publication number: 20120328521Abstract: The invention is directed to formulations of lipophilic Amyloid ?eta ligand stilbene based derivatives and more particularly to formulations which are administrable parentally e.g. intravenously wherein the lipophilic Amyloid ?eta ligand stilbene based derivative is a 19F or 18F-labeled radiopharmaceutical thereof. Further, the invention is directed to a method for sterile filtration of said suitable formulation.Type: ApplicationFiled: December 22, 2010Publication date: December 27, 2012Applicant: PIRAMAL IMAGING SAInventors: Carsten Olbrich, Michael Krause, Andreas Burkhard
-
Patent number: RE44338Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 2, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
-
Patent number: RE44354Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 9, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky